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AbstrAct
Objective In the 10 most common primary types with 
bone metastases, we aimed to examine survival, further 
stratifying on bone metastases only or with additional 
synchronous metastases.
Methods We included all patients aged 18 years and older 
with incident hospital diagnosis of solid cancer between 
1994 and 2010, subsequently diagnosed with BM until 
2012. We followed patients from date of bone metastasis 
diagnosis until death, emigration or 31 December 2012, 
whichever came first. We computed 1-year, 3-year and 
5-year survival (%) and the corresponding 95% CIs 
stratified on primary cancer type. Comparing patients with 
bone metastasis only and patients with other synchronous 
metastases, we estimated crude and adjusted HRs and 
corresponding 95% CI for mortality.
results We included 17 251 patients with bone 
metastasis. The most common primary cancer types 
with bone metastasis were prostate (34%), breast (22%) 
and lung (20%). One-year survival after bone metastasis 
diagnosis was lowest in patients with lung cancer (10%, 
95% CI 9% to 11%) and highest in patients with breast 
cancer (51%, 50% to 53%). At 5 years of follow-up, only 
patients with breast cancer had over 10% survival (13%, 
11% to 14%). The risk of mortality was increased for 
the majority of cancer types among patients with bone 
and synchronous metastases compared with bone only 
(adjusted relative risk 1.29–1.57), except for cervix, 
ovarian and bladder cancer.
conclusions While patients with bone metastases after 
most primary cancers have poor survival, one of ten 
patients with bone metastasis from breast cancer survived 
5 years.
IntrOductIOn
Bone is the third most common site of meta-
static disease in patients with cancer.1 2 Bone 
metastases occur in every cancer type, but are 
most common in patients with cancers of the 
breast, prostate or lung.2–4 Such metastases 
are often painful and can cause considerable 
morbidity,2 4 5 including a range of skeletal 
related events,6 and is associated with substan-
tial use of hospital resources.7 8
Population-based reports on length of 
survival after bone metastases from many 
primary cancer types are lacking. In patients 
with breast, prostate and renal cancer, the 
reported median survival ranges from 12 
to 33 months for patients with bone metas-
tases,9–14 and survival increases with longer 
time between primary diagnosis and such 
metastases.15 On the other hand, survival is 
low for patients with primary lung cancer and 
bone metastases, 1-year survival ranging from 
9.5% to 12%.16 17
Previous research has suggested that 
survival among patients with bone metastases 
is associated with tumour and other disease 
characteristics. In a clinical setting, having 
other synchronous metastases in addition to 
bone metastasis was associated with impaired 
prognosis compared with bone metastasis 
only in patients with primary gynaecolog-
ical or prostate cancer.11 18 For other cancer 
types, this information is not available in a 
population-based setting. We hypothesise 
that survival for other cancers will follow the 
above-mentioned pattern, being better when 
no synchronous metastases are observed.
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strengths and limitations of this study
 ► Strengths of this study include its large size and 
population-based design.
 ► The high-quality Danish medical databases provide 
complete hospital contact and follow-up of all 
patients, thereby limiting the risk of referral and 
diagnostic bias.
 ► Although the coding is reasonable accurate, the 
proportions of patients with bone metastases are 
likely to be underestimated.
 ► We used the date of hospital diagnosis of bone 
metastases as registered in the Danish National 
Patient Registry, this date may not be the same as 
the first evidence of metastasis.
 ► We only included synchronous metastases 
diagnosed prior to the bone metastasis, thus, the 
figure of 90% of patients having bone metastases 
only, reflects that bone was the first location of 
metastases.
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Thus, in the 10 most common solid cancers with bone 
metastasis, we aimed to estimate survival, and to compare 
mortality among patients with bone metastasis only with 
mortality of patients who were diagnosed with additional 
other synchronous metastases.
MAterIAl And MethOds
Study population
We conducted this population-based cohort study in 
Denmark, with about 5.6 million inhabitants, based on 
a linkage of prospectively collected data from Danish 
medical registries. Denmark is a welfare state with 
tax-funded universal access to healthcare, providing 
primary and secondary care without out-of-pocket 
expenses and partial reimbursement for most prescribed 
medications. Individual-level data from all Danish regis-
tries can be linked via the unique personal identifier, the 
CPR number, assigned at birth, registered in the Danish 
Civil Registration system (CRS).19
cancer patients with bone metastasis
We included all adult (over 18 years of age) residents of 
Denmark diagnosed with cancer in the Danish Cancer 
Registry from 1 January  1994 to 31 December 2010, 
and with a diagnosis of bone metastasis registered in the 
Danish National Patient Registry (DNPR) on or after 
the date of primary cancer diagnosis until 31 December 
2012.20 DNRP holds discharge diagnoses from all inpa-
tient admissions to Danish hospitals since 1977 and 
hospital outpatient clinic diagnoses since 1995. For each 
visit, the DNPR includes information on admission and 
discharge, procedures and up to 20 diagnoses. Since 1994, 
the diagnostic information has been coded according to 
the International Classification of Diseases, 10th Revision. 
All diagnostic codes are given in the online supplemen-
tary appendix.
We stratified patients with bone metastasis to bone 
metastasis at the time of primary cancer diagnosis or 
more than 3 months after primary cancer diagnosis. 
Cases of bone metastasis diagnosed more than 3 months 
after cancer diagnosis were further stratified into bone 
metastasis only (no other metastasis) or bone with other 
synchronous metastases, defined as patients having other 
metastases prior to diagnosis of bone metastases.
covariates
From the DNPR, we collected information on the 19 major 
non-psychiatric comorbidities in the Charlson Comor-
bidity Index (CCI) prior to diagnosis of bone metastasis,21 
using a modified version where any tumour, leukaemia, 
lymphoma and metastatic solid tumour is excluded in 
the calculation. Based on the CCI score, we defined three 
comorbidity levels: low (score of 0), medium (score of 
1–2) and high (score of 3+).
Follow-up
Patients were followed from diagnosis of bone metas-
tasis to date of death, emigration or 31 December 2012, 
whichever came first. Information on vital status (alive, 
dead, emigration) was obtained from the Danish CRS.19 
The CRS contains electronic records of age, gender, vital 
status and place of residence (address) for the entire 
Danish population since 1968, and is updated daily.
This study was approved by the Danish Data Protection 
Agency (Record Nr. 1-16-02-1-08). As this registry-based 
study did not involve patient contact, no separate 
permission from the Danish Scientific Ethics Committee 
was required, according to Danish legislation.
statistical analysis
We examined the 10 most common primary cancer types 
with bone metastases. For the three most common types: 
breast, prostate and lung, we investigated the distribution 
of bone metastases, stratified on bone metastasis presence 
at the time of primary cancer diagnosis or more than 3 
months after diagnosis. We computed 1-year, 3-year and 
5-year survival with corresponding 95% CIs using the 
Kaplan-Meier methods for all bone metastasis after all 
cancer types.
We further stratified on bone metastases only and 
bone plus other synchronous metastases, restricted to 
patients diagnosed with bone metastases more than 3 
months after primary cancer diagnosis. We calculated 
the median age at bone metastasis diagnosis and median 
time from cancer diagnosis to bone metastasis for each 
cancer type and computed Kaplan-Meier survival curves 
for this stratification. We calculated the percentage of 
patients with bone metastases only, compared with bone 
plus other synchronous metastases at the time of bone 
metastasis diagnosis. By Cox regression, we estimated 
HRs for death and the corresponding 95% CI separately 
for each primary cancer type, comparing bone metas-
tases only with bone and additional metastases. The 
proportional hazard assumption was fulfilled. The HR 
was adjusted for age, gender, CCI score and period of 
diagnosis.
We used SAS statistical software, V.9.2 (SAS Institute), 
for all statistical analyses.
results
In the 10 most common primary cancers with bone metas-
tasis, we identified 17 251 patients diagnosed between 
1994 and 2010, followed up for bone metastasis until the 
end of 2012. Prostate, breast and lung cancer were the 
most frequent primary cancer types, accounting for 34%, 
22% and 20% of patients with bone metastasis, respec-
tively. In table 1, the distribution of bone metastasis by 
cancers of the lung, prostate and breast are given over 
time. For breast and prostate cancer, the proportion 
developing bone metastasis is rather stable over time, 
taken into account a shorter follow-up for the last time 
period under investigation. However, for lung cancer 
there seems to be a slight increase in proportion over 
time.
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Table 1 Patients who develop bone metastasis by all breast, lung and prostate cancers over time, overall and stratified into 
bone metastasis at the time of primary cancer diagnosis or more than 3 months after primary diagnosis
Cancer type
Year of cancer 
diagnosis
Total number 
patients with 
cancer
n
Patients who develop bone metastasis
Total
At primary cancer 
diagnosis
More than 3 months 
after primary diagnosis
 n  % n  %  n %
Lung 1994–1997 13 713 445 3 291 2 154 1
1998–2001 14 419 633 4 333 2 300 2
2002–2006 19 504 1188 6 755 4 433 2
2007–2010 17 270 1137 7 785 5 352 2
Breast 1994–1997 13 623 936 7 143 1 793 6
1998–2001 15 145 1001 7 172 1 829 5
2002–2006 20 348 1223 6 314 2 909 4
2007–2010 19 893 629 3 236 1 393 2
Prostate 1994–1997 6041 1034 17 308 5 726 12
1998–2001 7774 1602 21 352 5 1250 16
2002–2006 13 588 2181 16 652 5 1529 11
2007–2010 15 454 1124 7 325 2 799 5
Table 2 One-year, 3-year and 5-year survival estimates with 95% CI after bone metastasis diagnosis (all) by primary cancer 
type
1-year survival % (95% CI) 3-year survival % (95% CI) 5-year survival % (95% CI)
Digestive organs
  Colon* 21 (18 to 25) 7 (5 to 10) 3 (2 to 5)
   Rectum 22 (18 to 26) 3 (2 to 5) 2 (1 to 3)
Respiratory organs
  Lung 10 (9 to 11) 2 (1 to 2) 1 (0.5 to 1)
Malignant melanoma 17 (12 to 22) 6 (4 to 10) 5 (3 to 8)
Breast 51 (50 to 53) 25 (23 to 26) 13 (11 to 14)
Female genital organs
  Cervix 18 (11 to 28) 6 (2 to 14) 2 (0 to 7)
  Ovary 33 (21 to 44) 15 (7 to 25) 8 (3 to 18)
Male genital organs
  Prostate 35 (34 to 37) 12 (11 to 13) 6 (5 to 7)
Urinary organs
  Kidney 29 (26 to 33) 10 (8 to 12) 5 (4 to 7)
  Bladder 13 (11 to 17) 5 (3 to 7) 3 (1 to 5)
*Including colonrectosigmoid.
survival
Survival after diagnosis of bone metastasis (all) varied 
widely by cancer type (table 2). One-year survival after 
bone metastasis was lowest in patients with lung cancer 
(10%, 95% CI 9% to 11%) and highest in patients with 
breast cancer (51%, 95% CI 50% to 53%). Three-year 
survival ranged from 2% for lung cancer (95% CI 1 to 2), 
12% (96% CI 11% to 13%) for prostate to 25% (95% CI 
23% to 26%) for breast cancer. At 5 years of follow-up, 
only patients with breast cancer among the solid tumours 
had over 10% survival (13%, 95% CI 11% to 14%).
bone metastasis only versus bone metastasis with other 
synchronous metastases
Median time from primary cancer diagnoses to bone 
metastasis, restricted to patients without bone metastasis 
within 3 months of being diagnosed with the primary 
cancer ranged from close to 1 year (eg, lung cancer, 
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Table 3 Median age (years) at bone metastasis diagnosis and median time (days) since primary cancer to bone metastasis by 
primary cancer type stratified on bone metastasis only or bone metastasis plus other synchronous metastasis. Patients with 
bone metastasis at or within 3 months of primary cancer diagnosis were excluded
N
Median age, years, 
at diagnosis, (IQR)
Median time, days, from 
primary cancer diagnosis to 
bone met only (IQR)
Median time, days, from 
primary cancer to Bone 
metastasis+other synchronous 
metastases (IQR)
Digestive organs
  Colon (incl rectosig.) 355 68 (60–76) 748 (341–1429) 778 (495–1216)
  Rectum 349 68 (60–76) 870 (414–1426) 1193 (500–1806)
Respiratory organs
  Lung 1239 66 (59–73) 295 (175–564) 279 (167–541)
Malignant melanoma 225 64 (61–73) 784 (437–1703) 961 (454–1872)
Breast 2924 63 (54–72) 1246 (336–2151) 1432 (451–2309)
Female genital organs
  Cervix 64 52 (45–65) 723 (473–1520) 574 (491–1229)
  Ovary 54 62 (51–68) 784 (444–1405) 987 (463–2572)
Male genital organs
  Prostate 4304 74 (68–80) 767 (411–1422) 748 (403–1352)
Urinary organs
  Kidney 346 66 (58–73) 545 (243–1306) 668 (60–1599)
  Bladder 438 71 (64–77) 463 (260–1027) 610 (336–999)
279–295 days) to several years (eg, breast cancer, about 
3.5–4 years) (table 3). Median time to bone metastasis was 
comparable for bone metastasis only and bone metastasis 
with synchronous metastasis.
For all patients with bone metastasis, except malig-
nant melanoma, around 90% of patients had only such 
metastasis (table 4). Survival curves for bone metastasis 
after specific primary cancers, with and without the pres-
ence of other metastases, are presented in figure 1. 
Table 4 shows the Cox regression comparing mortality 
for patients with and without additional metastases at 
the time of bone metastasis diagnosis. The crude risk 
for mortality is increased for patients with synchronous 
metastasis compared with bone metastasis only, except for 
ovary, cervix and bladder cancer, with crude HR ranging 
from 1.3 (95% CI 1.0 to 1.6) for malignant melanoma to 
HR=1.6 (95% CI 1.4 to 1.8) for prostate cancer (table 4) 
and did not change considerably when adjusted for age, 
gender, comorbidity and year of diagnosis.
dIscussIOn
In this large heterogeneous cohort of 17 251 patients with 
bone metastasis in the 10 specific primary cancer types 
where bone metastases are most commonly observed, we 
find that the prognosis after diagnosis of bone metastasis 
is depending on primary cancer type. Furthermore, the 
prognosis is poorer when other metastases are present at 
the time of bone metastasis diagnosis.
Strengths of this study include its large size and popu-
lation-based design, made possible through access to 
high-quality Danish medical databases providing a 
complete hospital contact and follow-up of all patients, 
thereby limiting the risk of referral and diagnostic bias. 
Our data derive from a wide range of unselected patients 
in real life and the generalisability may be transferrable to 
other population-based settings.
Our registry-based population approach also introduces 
some limitations. The validity of our findings depends 
on the completeness and the accuracy of reporting to 
the DNPR. The diagnoses registered in the DNPR as 
compared with a review of medical records have a high 
specificity, but the completeness was low, primary related 
to metastases without symptoms.22 Thus, although the 
coding is reasonably accurate, the proportions of patients 
with bone metastases are likely to be underestimated.22 It 
is possible that in lieu of other metastases, such as lung 
metastases, additional bone metastasis would to a lesser 
extent be recorded, this non-random misclassification 
would possibly influence the estimates, resulting in an 
even more increased risk of mortality among patients 
with additional metastases compared with bone only. 
On the other hand, if patients with other synchronous 
metastases do not have their bone metastasis recorded, 
they would not be included in the study, and therefore 
lead to selection bias, and possibly a lower mortality 
among the included patients. We only included synchro-
nous metastases diagnosed prior to the bone metastasis, 
thus the figure of 90% of patients having bone metastasis 
only, reflects that bone metastasis were located first, and 
that the patients may have developed other subsequent 
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Table 4 HRs and corresponding 95% CIs for mortality after bone metastasis, comparing patients with bone metastasis only 
and patients with additional synchronous metastases
Primary cancer N (%)
Median survival 
time (days) HR (95% CI) Adjusted* HR (95% CI)
Colon cancer Bone metastasis only 452 (91) 105 1.0 1.0
Bone+other synchronous 
metastases
47 (9) 95 1.38 (1.02 to 1.87) 1.48 (1.09 to 2.03)
Rectum cancer Bone metastasis only 361 (90) 114 1.0 1.0
Bone+other synchronous 
metastases
39 (10) 79 1.47 (1.06 to 2.05) 1.44 (1.03 to 2.03)
Lung cancer Bone metastasis only 2871 (84) 74 1.0 1.0
Bone+other synchronous 
metastases
532 (16) 61 1.20 (1.10 to 1.32) 1.27 (1.16 to 1.40)
Malignant 
melanoma
Bone metastasis only 172 (64) 95 1.0 1.0
Bone+other synchronous 
metastases
97 (36) 75 1.26 (0.97 to 1.63) 1.29 (0.99 to 1.69)
Breast cancer Bone metastasis only 3268 (86) 377 1.0 1.0
Bone+other synchronous 
metastases
521 (14) 170 1.42 (1.28 to 1.57) 1.47 (1.33 to 1.63)
Cervix cancer Bone metastasis only 67 (91) 98 1.0 1.0
Bone+other synchronous 
metastases
7 (9) 46 1.06 (0.48 to 2.33) 1.00 (0.42 to 2.38)
Ovarian cancer Bone metastasis only 54 (83) 170 1.0 1.0
Bone+other synchronous 
metastases
11 (17) 129 1.12 (0.56 to 2.23) 1.08 (0.51 to 2.29)
Prostate cancer Bone metastasis only 5726 (96) 210 1.0 1.0
Bone+other synchronous 
metastases
215 (4) 109 1.55 (1.35 to 1.78) 1.57 (1.36 to 1.80)
Kidney cancer Bone metastasis only 609 (77) 182 1.0 1.0
Bone+other synchronous 
metastases
186 (23) 105 1.33 (1.12 to 1.58) 1.41 (1.18 to 1.69)
Urinary bladder 
cancer
Bone metastasis only 513 (94) 68 1.0 1.0
Bone+other synchronous 
metastases
33 (6) 56 1.14 (0.79 to 1.65) 1.22 (0.84 to 1.77)
*Adjusted by gender, age, Charlson Comorbidity Index Score and period of diagnosis.
metastases not included in our analyses. Furthermore, 
we did not take into account the patients who developed 
a second primary cancer, which again might experience 
poorer survival. We here assumed that the bone metas-
tasis arose from the first cancer. Finally, we used the date 
of hospital diagnosis of bone metastasis as registered in 
the DNPR, and thus, the date may not be the same as the 
first evidence of metastasis, which may also explain why 
median survival is shorter than reported by others.
This study corroborates previous research findings 
regarding prognosis after bone metastasis.10–12 As noted 
by Ibrahim et al, most bone metastasis are secondary to 
breast, prostate and lung cancer.5 Generally, the 1-year 
survival rates observed in the present study are lower 
than other clinical based studies.11 12 For example, Drzy-
malski et al estimated a 1-year survival of 73% based on 
a study on patients in the Prostate Clinical Research 
Information System at the Dana-Farber Cancer Insti-
tute.11 It is possible that in countries with high levels 
of screening for prostate cancer, the bone metastasis 
may be detected earlier via elevated PSA screening, 
or with a higher proportion of castration naïve pros-
tate cancers, and therefore have a better prognosis 
than observed here. For breast cancer, patients with 
hormone receptor positive cancers can have a long 
survival even with bone metastasis. However, receptor 
status is not known in this study. Nonetheless, most 
other reports come from specialised cancer treatment 
facilities, thus conceivably encompass selected groups 
of patients and accordingly suffer from bias when 
compared with results of population-based studies 
applied to the real-life situation.
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Figure 1 Cumulative survival comparing bone metastasis only with bone metastasis and other synchronous metastases.
In accordance with our hypothesis and previous find-
ings,11 18 having other metastases impaired prognosis after 
bone metastasis diagnosis. Additional metastases might be 
indicative of a more aggressive primary tumour. However, 
since the patients with other synchronous metastases, in 
addition to bone, may have had their other metastasis 
for some time, it is not surprising that their mortality is 
higher, simply because a longer time had elapsed after the 
primary diagnosis. Nonetheless, as time from diagnosis of 
primary cancer to bone metastasis can be regarded as an 
intermediate variable, we have not controlled for this in 
an adjusted analysis.
Unfortunately, we did not have individual-level infor-
mation about the primary treatments and the specific 
bone-targeted therapy eventually received by the patients. 
We investigated a longtime course, and thus new treat-
ments implemented during the study period can confound 
the observed prognosis. Further studies are warranted 
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on incidence and survival of patients with bone metas-
tasis over time with respect to the bone-targeted therapy 
for the different cancer types, to examine the influence 
clinical options may have on prognosis. Furthermore, a 
detailed examination of the natural history of the patients 
with bone metastasis, including a detailed description of 
skeletal related events, is beyond the scope of this article, 
but also warrants further examination. Another area 
warranting further investigation is whether the outcome 
differs for the different solid primary tumours according 
to osteolytic versus osteoblastic bone metastases. None-
theless, as this is a population-based study covering all of 
Denmark, the generalisability of the study applies.
In conclusion, this population-based registry study 
with complete follow-up shows that there is a significant 
proportion of patients with long-term survival with bone 
metastasis in selected malignant diseases, such as breast 
cancer.
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